Use of phosphate binders in chronic kidney disease

Current Opinion in Nephrology and Hypertension

Volumn 22, Issue 4, 2013, Pages 413-420

  Ketteler, Markus ^a   Biggar, Patrick H ^a  

^a KLINIKUM COBURG   (Germany)

Author keywords

Calcification; Fibroblast growth factor 23; Hyperphosphatemia; Lanthanum; Phosphate binders; Sevelamer

Indexed keywords

CALCIUM CARBONATE; COLESTILAN; FERRIC HYDROXIDE; FIBROBLAST GROWTH FACTOR 23; LANTHANUM CARBONATE; NICOTINAMIDE; NICOTINIC ACID; PHOSPHATE; PHOSPHATE BINDING AGENT; SEVELAMER;

BLOOD VESSEL CALCIFICATION; BONE BIOPSY; CHRONIC KIDNEY DISEASE; DIETARY INTAKE; DISEASE COURSE; DRUG SCREENING; DRUG USE; FOLLOW UP; HEMODIALYSIS PATIENT; HUMAN; HYPERPHOSPHATEMIA; LONGEVITY; OBSERVATIONAL STUDY; OUTCOME ASSESSMENT; PATHOPHYSIOLOGY; PATIENT COMPLIANCE; PHOSPHATE BLOOD LEVEL; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROSPECTIVE STUDY; RENAL REPLACEMENT THERAPY; REVIEW;

ANIMALS; CHELATING AGENTS; HUMANS; HYPERPHOSPHATEMIA; KIDNEY; MEDICATION ADHERENCE; PHOSPHATES; PHOSPHORUS, DIETARY; RENAL DIALYSIS; RENAL INSUFFICIENCY, CHRONIC; TREATMENT OUTCOME;

EID: 84879212998     PISSN: 10624821     EISSN: 14736543     Source Type: Journal    
DOI: 10.1097/MNH.0b013e32836214d4     Document Type: Review

References (43)

1. Zhang QL, Rothenbacher D. Prevalence of chronic kidney disease in population-based studies: systematic review. BMC Public Health 2008; 8:117.
2. Couser WG, Remuzzi G, Mendis S, Tonelli M. The contribution of chronic kidney disease to the global burden of major noncommunicable diseases. Kidney Int 2011; 80:1258-1270.
3. Shanahan CM, Crouthamel MH, Kapustin A, Giachelli CM. Arterial calcification in chronic kidney disease: key roles for calcium and phosphate. Circ Res 2011; 109:697-7114.
4. Shuto E, Taketani Y, Tanaka R, et al. Dietary phosphorus acutely impairs endothelial function. J Am Soc Nephrol 2009; 20:1504-1512.
5. Block GA, Klassen PS, Lazarus JM, et al. Mineral metabolism, mortality, and morbidity in maintenance hemodialysis. J Am Soc Nephrol 2004; 15:2208-2218.
6. Floege J, Kim J, Ireland E, et al. Serum iPTH, calcium and phosphate, and the risk of mortality in a European haemodialysis population. Nephrol Dial Transplant 2011; 26:1948-1955.
7. Tonelli M, Pannu N, Manns B. Oral phosphate binders in patients with kidney failure. N Engl J Med 2010; 362:1312-1324.
8. Miyamoto K, Haito-Sugino S, Kuwahara S, et al. Sodium-dependent phosphate cotransporters: lessons from gene knockout and mutation studies. J Pharm Sci 2011; 100:3719-3730.
9. Moe SM, Drüeke TB, Block GA, et al. Kidney Disease: Improving Global Outcomes CKDMBDWG. KDIGO clinical practice guideline for the diagnosis, evaluation, prevention, and treatment of Chronic Kidney Disease Mineral and Bone Disorder (CKD-MBD). Kidney Int 2009; 76:S1-S130.
10. Ritz E, Hahn K, Ketteler M, et al. Phosphate additives in food: a health risk. Dtsch Arztebl Int 2012; 109:49-55.
11. Sullivan C, Sayre SS, Leon JB, et al. Effect of food additives on hyperpho-sphatemia among patients with end-stage renal disease: a randomized controlled trial. JAMA 2009; 301:629-635.
12. Cupisti A, Benini O, Ferretti V, et al. Novel differential measurement of natural and added phosphorus in cooked ham with or without preservatives. J Ren Nutr 2012; 22:533-540.
13. Daugirdas JT, Chertow GM, Larive B, et al. Effects of frequent hemodialysis on measures of CKD mineral and bone disorder. J Am Soc Nephrol 2012; 23:727-738.
14. Lopes AA, Tong L, Thumma J, et al. Phosphate binder use and mortality among hemodialysis patients in the Dialysis Outcomes and Practice Patterns Study (DOPPS): evaluation of possible confounding by nutritional status. Am J Kidney Dis 2012; 60:90-101.
15. Isakova T, Gutiérrez OM, Chang Y, et al. Phosphorus binders and survival on hemodialysis. J Am Soc Nephrol 2009; 20:388-396.
16. Qunibi WY, Hootkins RE, McDowell LL, et al. Treatment of hyperphospha-temia in hemodialysis patients: the Calcium Acetate Renagel Evaluation (CARE Study). Kidney Int 2004; 65:1914-1926.
17. Jean G, Lataillade D, Genet L, et al. Calcium carbonate, but not sevelamer, is associated with better outcomes in hemodialysis patients: results from the French ARNOS study. Hemodial Int 2011; 15:485-492.
18. Goodman WG, Goldin J, Kuizon BD, et al. Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N Engl J Med 2000; 342:1478-1483.
19. Ketteler M, Rix M, Fan S, et al. Efficacy and tolerability of sevelamer carbonate in hyperphosphatemic patients who have chronic kidney disease and are not on dialysis. Clin J Am Soc Nephrol 2008; 3:1125-1130.
20. Chertow GM, Burke SK, Raggi P, Treat to Goal Working Group. Sevelamer attenuates the progression of coronary and aortic calcification in hemodialysis patients. Kidney Int 2002; 62:245-252.
21. Block GA, Spiegel DM, Ehrlich J, et al. Effects of sevelamer and calcium on coronary artery calcification in patients new to hemodialysis. Kidney Int 2005; 68:1815-1824.
22. Zhang Q, Li M, Lu Y, et al. Meta-analysis comparing sevelamer and calcium-based phosphate binders on cardiovascular calcification in hemodialysis patients. Nephron Clin Pract 2010; 115:c259-c267.
23. Suki WN, Zabaneh R, Cangiano JL, et al. Effects of sevelamer and calcium-based phosphate binders on mortality in hemodialysis patients. Kidney Int 2007; 72:1130-1137.
24. Block GA, Raggi P, Bellasi A, et al. Mortality effect of coronary calcification and phosphate binder choice in incident hemodialysis patients. Kidney Int 2007; 71:438-441.
25. Di Iorio B, Bellasi A, Russo D, Investigators IS. Mortality in kidney disease patients treated with phosphate binders: a randomized study. Clin J Am Soc Nephrol 2012; 7:487-493.
26. Brandenburg VM, Schlieper G, Heussen N, et al. Serological cardiovascular and mortality risk predictors in dialysis patients receiving sevelamer: a prospective study. Nephrol Dial Transplant 2010; 25:2672-2679.
27. Oliveira RB, Cancela AL, Graciolli FG, et al. Early control of PTH and FGF23 in normophosphatemic CKD patients: a new target in CKD-MBD therapy? Clin J Am Soc Nephrol 2010; 5:286-291.
28. Sprague SM, Ross EA, Nath SD, et al. Lanthanum carbonate vs. sevelamer hydrochloride for the reduction of serum phosphorus in hemodialysis patients: a crossover study. Clinical Nephrol 2009; 72:252-258.
29. Gonzalez-Parra E, Gonzalez-Casaus ML, Galan A, et al. Lanthanum carbonate reduces FGF23 in chronic kidney disease Stage 3 patients. Nephrol Dial Transplant 2011; 26:2567-2571.
30. D'Haese PC, Spasovski GB, Sikole A, et al. A multicenter study on the effects of lanthanum carbonate (Fosrenol) and calcium carbonate on renal bone disease in dialysis patients. Kidney Int Suppl 2003; 85:S73-S78.
31. Lacour B, Lucas A, Auchère D, et al. Chronic renal failure is associated with increased tissue deposition of lanthanum after 28-day oral administration. Kidney Int 2005; 67:1062-1069.
32. Hutchison AJ, Barnett ME, Krause R, Siami GA, Lanthanum Carbonate Study Group. Lanthanum carbonate treatment, for up to 6 years, is not associated with adverse effects on the liver in patients with chronic kidney disease Stage 5 receiving hemodialysis. Clin Nephrol 2009; 71:286-295.
33. de Francisco AL, Leidig M, Covic AC, et al. Evaluation of calcium acetate/magnesium carbonate as a phosphate binder compared with sevelamer hydrochloride in haemodialysis patients: a controlled randomized study (CALMAG study) assessing efficacy and tolerability. Nephrol Dial Transplant 2010; 25:3707-3717.
34. Massy ZA, Drueke TB. Magnesium and outcomes in patients with chronic kidney disease: focus on vascular calcification, atherosclerosis and survival. Clin Kidney J 2012; 5 (Suppl 1):i52-i61.
35. Locatelli F, Dimkovic N, Pontoriero G, et al. Effect of MCI-196 on serum phosphate and cholesterol levels in haemodialysis patients with hyperpho-sphataemia: a double-blind, randomized, placebo-controlled study. Nephrol Dial Transplant 2010; 25:574-581.
36. Wüthrich RP, Chonchol M, Covic A, et al. Randomized clinical trial of the iron-based phosphate binder PA21 in hemodialysis patients. Clin J Am Soc Nephrol 2013; 8:280-289.
37. Dwyer JP, Sika M, Schulman G, et al., Collaborative Study Group. Doseresponse and efficacy of ferric citrate to treat hyperphosphatemia in hemodialysis patients: a short-term randomized trial. Am J Kidney Dis 2013; 61:759-766.
38. Maccubbin D, Tipping D, Kuznetsova O, et al. Hypophosphatemic effect of niacin in patients without renal failure: a randomized trial. Clin J Am Soc Nephrol 2010; 5:582-589.
39. Cheng SC, Young DO, Huang Y, et al. A randomized, double-blind, placebocontrolled trial of niacinamide for reduction of phosphorus in hemodialysis patients. Clin J Am Soc Nephrol 2008; 3:1131-1138.
40. Block GA, Wheeler DC, Persky MS, et al. Effects of phosphate binders in moderate CKD. J Am Soc Nephrol 2012; 23:1407-1415.
41. Hill KM, Martin BR, Wastney ME, et al. Oral calcium carbonate affects calcium but not phosphorus balance in stage 3-4 chronic kidney disease. Kidney Int 2013; 83:959-966.
42. Karamanidou C, Clatworthy J, Weinman J, Horne R. A systematic review of the prevalence and determinants of nonadherence to phosphate binding medication in patients with end-stage renal disease. BMC Nephrol 2008; 9:2.
43. Chiu YW, Teitelbaum I, Misra M, et al. Pill burden, adherence, hyperpho-sphatemia, and quality of life in maintenance dialysis patients. Clin J Am Soc Nephrol 2009; 4:1089-1096.